Augmedix (NASDAQ:AUGX – Get Free Report) was downgraded by equities analysts at B. Riley from a “strong-buy” rating to a “hold” rating in a report issued Friday, Zacks.com reports.

Other equities research analysts have also issued reports on the company. Lake Street Capital lowered their price target on Augmedix from $8.00 to $3.50 and set a “buy” rating on the stock in a research report on Tuesday, May 14th. Evercore ISI lowered Augmedix from an “outperform” rating to an “inline” rating and lowered their price target on the company from $5.00 to $1.50 in a research report on Tuesday, May 14th. Finally, Maxim Group lowered Augmedix from a “buy” rating to a “hold” rating and set a $5.00 price target on the stock in a research report on Tuesday, May 14th.

Get our latest stock analysis on Augmedix

Augmedix shares surge 146.6%

NASDAQ AUGX opened at $2.26 on Friday. The company has a market cap of $110.67 million, a PE ratio of -5.26, and a beta of -0.27. Augmedix has a one-year low of $0.73 and a one-year high of $6.25. The stock’s 50-day simple moving average is $1.00 and its 200-day simple moving average is $3.01. The company has a debt-to-equity ratio of 0.73, a current ratio of 2.04, and a quick ratio of 2.04.

Augmedix (NASDAQ:AUGX – Get Free Report) last released its quarterly earnings results on Monday, May 13. The company reported ($0.12) EPS for the quarter, which topped analysts’ consensus estimates of ($0.12). The company had revenue of $13.47 million for the quarter, compared to analyst estimates of $13.25 million. Augmedix had a negative return on equity of 178.34% and a negative net margin of 41.95%. As a group, sell-side analysts are predicting that Augmedix will post -0.45 EPS for the current fiscal year.

Institutional inflow and outflow

Several hedge funds and other institutional investors have recently made changes to their positions in AUGX. Russell Investments Group Ltd. increased its position in shares of Augmedix by 292.0% in the 4th quarter. Russell Investments Group Ltd. now owns 891,077 shares of the company’s stock worth $5,213,000 after purchasing an additional 663,778 shares in the last quarter. Parkman Healthcare Partners LLC increased its position in shares of Augmedix by 170.1% in the 4th quarter. Parkman Healthcare Partners LLC now owns 1,015,814 shares of the company’s stock worth $5,943,000 after purchasing an additional 639,732 shares in the last quarter. Ancora Advisors LLC increased its position in shares of Augmedix by 102.7% in the 1st quarter. Ancora Advisors LLC now owns 444,660 shares of the company’s stock worth $1,819,000 after purchasing an additional 225,330 shares in the last quarter. Hood River Capital Management LLC increased its position in shares of Augmedix by 79.0% in the first quarter. Hood River Capital Management LLC now owns 490,238 shares of the company’s stock worth $2,005,000 after purchasing an additional 216,339 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Augmedix by 16.0% in the first quarter. Vanguard Group Inc. now owns 1,302,424 shares of the company’s stock worth $5,327,000 after purchasing an additional 179,534 shares in the last quarter. 87.11% of the shares are currently held by institutional investors.

Company profile Augmedix

(Get free report)

Augmedix, Inc. provides remote medical documentation solutions and live clinical support services in the United States. The platform offers Augmedix Live, which provides synchronous medical note documentation and point-of-care support; Augmedix Go Assist, which provides asynchronous medical documentation based on previously recorded visits; Augmedix Prep, which provides patient demographics, medical history, medication changes, and other points from the patient’s medical record; and Augmedix Go, an autonomous, ambient AI mobile software application that provides fully automated medical documentation based on recorded visits.

Also see

Receive daily news and reviews for Augmedix – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings on Augmedix and related companies with MarketBeat.com’s FREE daily email newsletter.